A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
We propose a focused, prospective pilot clinical imaging trial to evaluate 11C-Gln PET/CT
followed by 18F-FSPG PET/CT in 20 HNSCC patients. Imaging metrics that are common to PET
(e.g. SUVmax, peak or mean) will be determined.
This study will also allow the acquisition of additional safety and biodistribution data, as,
to date, only a limited number of patients have been evaluated with 11C-Gln as a direct PET
imaging biomarker of Gln uptake. To date, no adverse side effects have been observed. We do
not anticipate any toxicity since this tracer is a naturally-occurring essential amino acid
in high abundance and is administered at sub-pharmacologic doses.
A long-term goal of these preliminary studies is to validate the utility of Gln PET imaging
metrics for HNSCC and to expand this imaging technique to additional patients in prospective
cohorts of patients with HNSCC.